Monitor for actual sales by the selling stockholders, particularly ARCH Venture Fund, Gates Frontier, and Explore Investments, as these could create downward pressure on the stock. The recent $25M in insider buying suggests confidence in the company's prospects despite this resale registration. The lack of proceeds to the company means this is purely a liquidity event for existing investors rather than a capital raise.
Price Chart
Executive Summary
Lyell Immunopharma has filed an S-3 shelf registration to allow selling stockholders to resell 1,952,360 shares of common stock acquired in a private placement on March 6, 2026. The company will not receive any proceeds from these sales, which were originally purchased at $25.61 per share in a milestone closing. The registration enables liquidity for institutional investors including ARCH Venture Fund, Gates Frontier, and Explore Investments.
Key Financial Metrics
Key Facts
- S-3 filing registers 1,952,360 shares for resale by selling stockholders from a March 6, 2026 private placement
- Company will not receive any proceeds from the resale of these shares
- Shares were acquired at $25.61 per share in a milestone closing under a July 2025 Securities Purchase Agreement
- Selling stockholders include ARCH Venture Fund XIII, Euler Fund, Gates Frontier LLC, and Explore Investments LLC
- Registration fee of $5,200.99 calculated based on $19.29 per share (average of March 27, 2026 Nasdaq high/low)
- Company recently had $25M in insider buying over the past 30 days
Financial Impact
Potential dilution of 8.4% based on 23,328,390 shares outstanding, with maximum aggregate offering price of $37.66M
Risk Factors
- Potential share price pressure if selling stockholders liquidate positions
- Perception of negative sentiment despite company not receiving proceeds
- Concentration risk with four primary selling stockholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-142213 |
| Document: d122816dexfilingfees.htm | 0001193125-26-142213 |
| Document: d122816dex51.htm | 0001193125-26-142213 |
| Document: d122816dex231.htm | 0001193125-26-142213 |
| Document: 0001193125-26-142213-index-headers.html | 0001193125-26-142213 |
| Document: 0001193125-26-142213-index.html | 0001193125-26-142213 |
| Document: 0001193125-26-142213.txt | 0001193125-26-142213 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access